EyePoint Pharmaceuticals, Inc. — Director's Dealing 2016

Jan 5, 2016

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: pSivida Corp. (PSDV)
CIK: 0001314102
Period of Report: 2016-01-04

Reporting Person: Ross Leonard S (Vice President, Finance)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2016-01-04	Common Stock	M	5000	$1.81	Acquired	5000	Direct
2016-01-04	Common Stock	S	5000	$4.70	Disposed	0	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2016-01-04	Stock Option (Right to Buy)	$1.81	M	5000	Disposed	2019-06-25	Common Stock (5000)	Direct

Footnotes

F1: Shares sold pursuant to a Rule 10b5-1 Sales Plan adopted by the Reporting Person with respect to the Common Stock of the Issuer.

F2: The option was granted on 06/25/2009 and vested in four equal annual installments beginning on the first anniversary of the date of grant.

F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.61 to $4.74. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.